US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Health officials are urging older adults to get vaccinated against respiratory syncytial virus (RSV). NHS England announced ...

This is the season for a rise in RSV cases. We talk to a local doctor on how to treat and stop the spread. Click here to ...

Inhalon Biopharma's inhaled RSV antibody treatment will enter human trials marking a potential breakthrough in respiratory ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) as part of FluCamp. Inhalon’s candidate IN-002 will be investigated ...

“The treatment paradigm for respiratory infections is ripe for disruptive innovation. Preventive immunizations are underutilized, especially in RSV, where vaccine usage is now expected to be one ...